Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy

  • STATUS
    Recruiting
  • End date
    Mar 3, 2023
  • participants needed
    34
  • sponsor
    Yonsei University
Updated on 3 February 2021

Summary

Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer. The recent study showed that HER2 overexpression or amplification is noted about 5-15% of total biliary tract cancer patients and have shown efficacy in small basket trials. The aim of this study is to evaluate the efficacy and safety of trastuzumab in the combination of mFOLFOX for gemcitabine+cisplatin refractory biliary tract cancer patients.

Description

This phase II study is designed to see whether trastuzumab-pkrb+FOLFOX is active as 2nd or 3rd line treatment for HER2-positive biliary tract cancer patients.

Details
Condition HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Treatment HERZUMA+mFOLFOX
Clinical Study IdentifierNCT04722133
SponsorYonsei University
Last Modified on3 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically documented recurred/metastatic/unresectable biliary tract cancer, including gallbladder cancer, intrahepatic, extrahepatic cholangiocarcinoma, or ampulla of vater cancer
Histologically confirmed HER2 positive biliary tract cancer. HER2-positive tumor was defined as either IHC 3+ or IHC 2+ in combination with ISH +, or ERBB2 amplification (6 copies) by tumor tissue NGS
Recurred/metastatic/unresectable biliary tract cancer patient whose disease progression was confirmed by imaging modality after gemcitabine+cisplatin containing 1st line palliative chemotherapy regimen. Previous lines should be one or two (immunotherapy monotherapy not counted)
be willing and able to provide written informed consent/assent for the trial
be at least 19 years of age on day of signing informed consent
have measurable disease based on RECIST (Response Evaluation Criteria In Solid Tumors) version 1.1
have a performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) Performance Scale
demonstrate adequate organ function
No severe valvular or arrhythmic cardiac disease with LVEF 50%
female subject of childbearing potential should have a negative urine or serum pregnancy or be willing to use birth control

Exclusion Criteria

Previous treatment history of oxaliplatin containing chemotherapy, anti-HER2 targeting treatment (trastuzumab, neratinib, lapatinib, and etc)
has had a prior anti-cancer chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., Grade 1 or at baseline) from adverse events due to agents administered
has a known additional malignancy that is progressing or requires active treatment within 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin and thyroid cancer that has undergone potentially curative therapy or in situ cervical cancer
has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
has known history or evidence of any disease, treatment, or laboratory results that would inhibit the patient's participation to the study
Has clinically significant cardiac disease, including congestive heart failure NYHA grade 2, uncontrolled hypertension, QTcF > 470 msec or QT prolong syndrome, recent myocardiac infarction or unstable angina history
has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
has known active Hepatitis B (HBsAg reactive and HBV DNA 100 copies/ml) or Hepatitis C (anti-HCV reactive and HCV RNA [qualitative] is detected)
has received a live vaccine within 30 days of planned start of study therapy
has an active infection requiring systemic therapy
has history of severe adverse event or allergic reaction to 5-FU, leucovorin, oxaliplatin or trastuzumab
need O2 supply or show dyspnea on rest due to advanced malignancy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note